Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-11-07
Schrödinger, Inc.
Schrödinger sells molecular simulation, workflow software, and cloud tools for drug and materials discovery, and also earns collaboration, milestone, and royalty economics from partnered programs.
ai biotech cloud healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Trusted discovery software with rerating potential
The core case is a cleaner, stickier software story rather than a speculative therapeutic windfall. If AI features become governed workflow spend instead of demoware, the equity can compound at a healthy mid-teens rate.

Analysis

Thesis
Over five years, Schrödinger can shift from a respected computational chemistry vendor into a more deeply embedded discovery operating layer, with hosted delivery, Bunsen, Predictive Tox, and selective downstream economics lifting spend per customer faster than reported revenue noise suggests today.
Last Economy Alignment
Cheaper AI and compute should increase molecule-design throughput, which benefits Schrödinger’s validated workflows and usage-led pricing. The upside is real but not maximal because customers still control lab budgets, data, and much of the surrounding orchestration stack.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.3x (from 5 most recent analyses)
Reasoning
The upside is driven more by better value capture than by blue-sky market creation. If hosted software keeps becoming the default delivery model, new AI modules convert into standard enterprise spend, and collaborator economics remain additive rather than distracting, investors can value the business as a stickier discovery system of record. That supports a credible doubling-plus outcome, but not a 10x moonshot.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The key risk is value capture, not scientific relevance. Schrödinger must prove that AI-driven workflow expansion turns into repeatable ACV and usage growth, while keeping hosted economics attractive enough to offset revenue-recognition noise and collaborator lumpiness. If customers use the science but keep governance and orchestration elsewhere, the stock may stay only modestly re-rated.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.48
It controls a trusted layer where drug teams run simulations, store results, and review decisions, so cheaper AI can send more work through its system. The risk is that customers may keep the real control points in-house and use cheaper models underneath, limiting how much extra value Schrödinger can capture.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$29.57
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case